Company Logo

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or continue ADHD medications during breastfeeding and pregnancy is a challenge for women suffering from the condition. There are few data on how exposure to ADHD for a long time could affect the pregnant fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems such as hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Pregnant women who take ADHD medications need to balance the advantages of taking them against potential risks to the foetus. Doctors don't have enough data to provide clear recommendations however they can provide information about risks and benefits to aid pregnant women in making informed choices.

A study published in Molecular Psychiatry concluded that women who took ADHD medication in early pregnancy were not at a higher risk of fetal malformations, or structural birth defects. Researchers used a vast population-based study of case-control to evaluate the incidence of major structural birth defects in babies born to mothers who had taken stimulants in the early stages of pregnancy, as well as those who had not. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure correct classification of the cases and to reduce the possibility of bias.

However, the researchers' study had its limitations. The researchers were unable to, in the first place to distinguish the effects triggered by the medication from the disorder. This limitation makes it difficult to determine whether the limited associations observed in the groups that were exposed result from medication use or confounding by comorbidities. The researchers also did not look at the long-term effects for the offspring.

The study did reveal that babies whose mothers had taken ADHD medications during pregnancy were at slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or had taken off their medication prior to or during pregnancy. The reason for this was central nervous system-related disorders, and the higher risk of admission was not found to be influenced by the stimulant medications were used during pregnancy.

Women who were taking stimulant adhd medication uk medication during pregnancy also had an elevated risk of having a caesarean birth or having a child with an low Apgar score (less than 7). These increases appear to be independent of the type of medication used during pregnancy.

The research suggests that the risk of a small amount with the use of ADHD medications during the early stages of pregnancy could be offset by the higher benefit to both mother and child of continuing treatment for the woman's condition. Physicians should discuss the issue with their patients and, if possible, assist them in developing strategies to improve coping skills which can reduce the effects of her disorder on her daily functioning and relationships.

medication given For adhd Interactions

Doctors are increasingly faced with the decision of whether to maintain treatment or stop it during pregnancy as more women are diagnosed with ADHD. Often, these decisions are made in the absence of solid and reliable evidence regardless, so doctors must weigh their knowledge about their experiences, the experiences of other doctors, and what research suggests on the subject, along with their own best judgment for each patient.

Particularly, the subject of potential risks to the infant can be difficult. The research on this subject is based on observations instead of controlled studies and many of the findings are conflicting. Additionally, the majority of studies limit their analysis to live births, which may underestimate the severity of teratogenic effects that could lead to abortion or termination of the pregnancy. The study that is discussed in the journal club addresses these limitations by analyzing information on deceased and live births.

The conclusion: While some studies have shown a positive association between ADHD medications and the risk of certain birth defects, others have found no connection, and most studies have a neutral or slight negative effect. In each case it is imperative to conduct a thorough analysis of the benefits and risks must be performed.

For a lot of women with ADHD and ADD, the decision to discontinue medication can be difficult, if not impossible. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can cause depression and feelings of being isolated. In addition, a decrease in medication can affect the ability to complete jobs and drive safely that are crucial aspects of a normal life for many people suffering from ADHD.

She suggests that women who are unsure about whether or not to discontinue medication due to their pregnancy, consider educating family members, friends, and coworkers on the condition, its impact on daily functioning, and on the benefits of keeping the current treatment plan. It can also help women feel supported in her decision. It is important to remember that certain drugs can be absorbed through the placenta so if the patient decides to stop her ADHD medication during pregnancy and breastfeeding, she must be aware that the effects of the drug could be transferred to the child.

Birth Defects and Risk of

As the use and use of ADHD medications to treat the symptoms of attention deficit disorder hyperactivity disorder (ADHD) increases, so does concern about the possible effects of the drugs on foetuses. A recent study published in the journal Molecular Psychiatry adds to the body of information on this topic. Researchers used two huge data sets to study over 4.3 million pregnancy and determine whether stimulant medications increased the risk of birth defects. While the overall risk is low, the researchers found that exposure in the first trimester to ADHD medications was linked to an increase in the risk of specific heart defects, such as ventriculo-septal defect (VSD).

The researchers of the study didn't discover any connection between the use of early medications and congenital anomalies such as facial deformities or club feet. The findings are in line with previous studies that have shown the presence of a small, but significant increase in the risk of heart malformations in women who started taking ADHD medications before the birth of their child. This risk increased during the latter part of pregnancy when a large number of women decided to stop taking their medication.

Women who were taking ADHD medication during the first trimester were more likely require a caesarean delivery, have a low Apgar after birth and had a baby that required help breathing at birth. However, the authors of the study were unable to eliminate bias due to selection by limiting the study to women who didn't have any other medical issues that could have contributed to these findings.

The researchers hope their research will help inform the clinical decisions of doctors who treat pregnant women. They recommend that, while the discussion of risks and benefits is important but the decision to stop or continue treatment should be based on each woman's requirements and the severity of her ADHD symptoms.

The authors warn that, even though stopping the medication is a possibility to consider, it is not advised due to the high prevalence of depression and mental health issues in women who are expecting or who have recently given birth. Further, research shows that women who stop taking their medications will have a difficult adjustment to life without them once the baby is born.

Nursing

The responsibilities of a new mother can be overwhelming. Women with ADHD who must work through their symptoms while attending physician appointments, getting ready for the arrival of their child and getting used to new routines at home are often faced with a number of difficulties. Many women opt to continue taking their ADHD medication during pregnancy.

The risk to a breastfeeding infant is minimal because the majority of stimulant medications is absorbed through breast milk in low amounts. However, the rate of exposure to medications by the newborn may differ based on the dosage, frequency it is administered, and at what time the medication is administered. In addition, individual medications enter the body of the baby differently through the gastrointestinal tract and breast milk and the impact of this on a newborn isn't well known.

Because of the lack of research, some physicians might be tempted to stop taking stimulant drugs during the course of pregnancy. This is a difficult decision for the patient, who must weigh the benefit of continuing her medication with the potential dangers to the foetus. In the meantime, until more information is available, GPs can inquire about pregnant patients whether they have a background of ADHD or if they are planning to take medication during the perinatal stage.

A increasing number of studies have proven that most women can safely continue taking their ADHD medication during pregnancy and breastfeeding. In the end, an increasing number of patients opt to do this and after consulting with their doctor, they have found that the benefits of maintaining their current medication outweigh any risks.

Women who suffer from ADHD who are planning to nurse should seek the advice of a specialist psychiatrist before becoming pregnant. They should discuss their medication with their prescriber and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation is also required to help pregnant women with ADHD recognize the signs and underlying disorder. They should also learn about treatment options and strengthen strategies for coping. This should be a multidisciplinary effort together with obstetricians, GPs and psychiatry. Counselling for pregnancy should include discussion of a management plan for both the mother and child, and monitoring for signs of deterioration and the need for adjustments to the medication regimen.